OPTIONS X
28 August - 01 September 2019
Singapore

 

CALL FOR LATE BREAKER ABSTRACTS


General Rules | How to send Abstracts | General Submission Guidelines | Abstract Submission Topics | Important Dates to Note | Terms and Conditions | Frequently Asked Questions | Important Links


 

OPTIONS X for the Control of Influenza (OPTIONS X), held in Singapore from 28th August to 1st September 2019, invites you to submit abstracts of original research related to influenza.

Late breaker abstracts must be submitted electronically through the OPTIONS X website. The final date for all late breaker abstracts to be submitted will be Monday, 15 July 2019, 11:59p.m. SGT. Late breaker Abstracts received after this date will not be accepted.

  • A. GENERAL RULES
    1. Types of Presentation
      1. Oral Presentations
        Presenters have 10 minutes to present, and 2 minutes for discussion.
      2. Poster Presentations
        There will be a dedicated area for posters and poster for interactions with poster presenters.
        Selected posters will be chosen for presentation at the session.
      3. Prizes will be awarded to the top oral and poster presentations. Details will be announced shortly.

    2. Late Breaker Abstract Receipt Confirmation
      1. Upon successful submission, authors will receive an automated acknowledgement via email.
      2. Lack of acknowledgement will indicate that the abstract was not received. Please contact us if the abstract you submitted is not followed by an acknowledgement.
      3. Late breaker abstracts must be received by:
        • Closing date: Monday, 15 July 2019, 11:59 p.m. SGT
      4. Late breaker abstracts received after this date will not be accepted.

    3. Notification of Acceptance
      1. The Presenting Author of each abstract accepted will be notified by email.
        Accepted abstracts will be notified by:
        • Late Breaker Notification Date: by Wednesday, 31 July 2019
      2. Late Breaker abstracts notification may also be found on “Abstract Page” of the Conference website. Simply logon using your userid and password to view your abstract.

    4. Publication
      1. Upon acceptance of your abstract, the presenting author must register for the conference to present at the Oral Session or Poster Presentation.
      2. ii. The abstract will be published on the Conference Website only if the presenting author is registered, and full payment received by Friday, 9 August 2019, 6:00 p.m. SGT.

  • B. HOW TO SEND ABSTRACTS
    • Abstracts can only be submitted via the website. Abstracts sent by other means will not be accepted.
    • Should you experience any problems, please contact:
      OPTIONS X Abstract Team 
      Phone: +(65) 6379 5261 / +(65) 6379 5267
      Fax: +(65) 6475 2077
      Email: optionsxsg@acedaytons-direct.com 

  • C. GENERAL SUBMISSION GUIDELINES
    1. Abstract must be submitted via the Conference Website.
    2. Abstracts must be in English Only
    3. Abstract should be as informative as possible, with the conclusion supported with data.
    4. Abstracts should be structured to include the following four separate sections and should reflect the quality, originality, and completeness of the abstract:
      1. Introduction and objectives: background and purpose of the study.
      2. Methods: describe pertinent experimental procedures.
      3. Results: summarise the results of the research.
      4. Conclusion: state the main conclusion(s).
    5. Additional guide to the abstract structure
      1. The title must be brief, concise, and in CAPITAL LETTERS
      2. The abstract body has a maximum of 300 words only
      3. Input the co-authors details in the submission form separately. Do NOT identify author(s) or institution(s) in the main text.
      4. Do not include references in the abstract.
      5. Please use standard abbreviations, generic drug names, and place unusual abbreviations or acronyms in parentheses after first use.
      6. Please use the guide on abstract categories to select the most appropriate category
      7. You are allowed to upload either one graph, figure, or table.
    6. After submission of the abstract and before the closing date, you may continue to edit the abstract.
    7. Abstracts will be judged solely on the basis of the data submitted in the abstract.

  • D. ABSTRACT SUBMISSION TOPICS
Virology and Pathogenesis
  1. Cellular & Molecular Virology
    • Cellular responses and viral replication
  2. Emerging Influenza Viruses
    • Animal influenza viruses with high risk of emergence in humans, zoonotic and one health studies
  3. Host-Pathogen Interactions
    • Viral determinants of pathogenesis, and host responses post-infection
  4. Immune Response to Infection
    • Studies of cell mediated and humoral immunity in humans and animals following influenza infection
  5. Influenza Evolution & Human Ecology
    • Evolutionary studies of human and animal influenza
  6. Influenza Glycobiology
    • Studies related to virus-glycan interactions; Role of glycans in viral infection
  7. NextGen/Universal Vaccines
    • Novel approaches to achieve next generation and broadly reactive influenza vaccines
  8. Non-Human Influenza Viruses
    • Studies of influenza infection in non-human hosts
  9. Virus Pathogenesis & Transmission
    • Molecular determinants of the pathogenesis and transmission of human and animal influenza viruses
  10. Viral Replication
Clinical Sciences
  1. Avian & Zoonotic Influenza - Human Infections
    • Clinical characteristics and clinical aspects of human infections with avian or swine influenza A viruses.
  2. Clinical Trials - Treatment and prevention
    • RCTs, observational studies and meta-analyses of observational data
  3. Diagnostics and Disease Markers
    • Human studies, not in animal models or testing in animals (birds, swine).
  4. Special Populations
    • Clinical aspects, unusual syndromes, in young children, minority/aboriginal populations, underserved, rural, immunosuppressed, pregnant women, etc.
  5. Therapeutics – Antivirals
    • (Clinical Efficacy/Effectiveness, Pharmacokinetics, Resistance)
  6. Therapeutics – Immunomodulators, Supportive care, Others
  7. Clinical Trials – Study designs, Clinical endpoints
  8. Non-pharmaceutical Interventions – Clinical aspects
  9. Development of Human Disease
    • Development and pathogenesis of human disease including immune response
Public Health
  1. Disease Burden & Severity
  2. Epidemiology & Transmission
    • Epidemiology of influenza in humans, animals, or zoonotic infections
  3. Pandemic Preparedness
    • Preparedness methodology or models
  4. Human Sero-Epidemiology Studies
    • Large scale sero-epidemiology studies that estimate disease burden
  5. Surveillance & Forecasting
    • Disease surveillance and models to forecast disease spread, burden and impact
  6. Vaccine Effectiveness/Impact
    • Field studies to determine effectiveness of impact in humans or animals
  7. Public health aspects
    • Non-Pharmaceutical interventions
  8. Pharmaco-economics, Cost-Effectiveness Studies
    • Economic, cost-effectiveness, or health technology assessments of pharmaceutical and non-pharmaceutical interventions
Co-Infection
  1. Co-infection Models
  2. Bacterial Co-infections with Influenza
  3. Viral Co-infections with Influenza

IMPORTANT DATES TO NOTE

Monday, 15 July 2019
11:59 p.m. SGT
Wednesday, 31 July 2019 Friday, 9 August 2019
6:00 p.m. SGT
Closing of Abstracts Submission Final Notification of Abstracts Acceptance Payment Deadline